Aratana Therapeutics


Credit Suisse Weighs in on Aratana Therapeutics (PETX) 2Q Earnings; All Eyes on Galliprant

Credit Suisse analyst Erin Wilson weighed in on Aratana Therapeutics (NASDAQ:PETX), after the pet biopharmaceutical company reported second-quarter results, posting EPS of ($0.48), below Wilson’s projection of ($0.

Monday Morning Pre-Market Insights: Global X Funds (GREK), Sarepta Therapeutics (SRPT), Gannett Co., Inc. (GCI), Aratana Therapeutics Inc (PETX)

Global X Funds (NYSEARCA:GREK) plummeted -17% in pre-market trading to $9.75 after the European Central bank announced it would not expand Greece’s emergency …

Aratana: Public Offering Eliminates Financial Overhang, Says William Blair

In a research report issued today, William Blair analyst John Kreger assigned an Outperform rating on Aratana Therapeutics (NASDAQ:PETX), following the company’s public …

William Blair Maintains Outperform On Aratana Following AT-003 Positive Readout In Pilot Study

In a research report issued yesterday, William Blair analyst John Kreger maintained an Outperform rating on Aratana Therapeutics (NASDAQ:PETX), following yesterday’s news that …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts